Leerink Partners analyst David Risinger maintains $Johnson & Johnson (JNJ.US)$ with a buy rating, and sets the target price at $182.
According to TipRanks data, the analyst has a success rate of 62.9% and a total average return of 15.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Following a Q3 report which was described as being broadly consistent with projections, with the Pharma segment outperforming and the Medtech segment underperforming expectations, there were slight revisions made to the anticipated figures.
Following the third-quarter report, there's an optimistic perspective on Johnson & Johnson due in part to the progression of the talc litigation settlement proposal. Additionally, the company has successfully completed several acquisitions in the medical technology sector and provided commentary setting expectations for 2025, reinforcing a positive outlook on the stock.
Johnson & Johnson outperformed expectations with a 5.6% underlying growth excluding Covid impact, largely propelled by the strength in Innovative Medicine, albeit with MedTech experiencing seasonal patterns and challenges in the Asia Pacific region. Post Q3 results, it's evident that the company is making significant operational strides, with a focus on executing its pipeline development effectively.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
